# Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

> **NCT00862849** · PHASE1 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Lispro
- **DRUG:** Regular Human Insulin
- **DRUG:** rHuPH20

## Key facts

- **NCT ID:** NCT00862849
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862849, "Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00862849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*